PCSK9 inhibitors represent the most significant advance in LDL cholesterol management since statins. They can reduce LDL-C by an additional 50–65% on top of maximally tolerated statin therapy — bringing even familial hypercholesterolaemia patients to guideline-recommended targets. Three drugs are now approved: two monoclonal antibodies (evolocumab, alirocumab) and an siRNA (inclisiran). This guide explains the biology behind PCSK9, how each drug works, the clinical trial evidence, and how to select between PCSK9 inhibitors and statins for different patient profiles.
What Is PCSK9?
PCSK9 (proprotein convertase subtilisin/kexin type 9) is a serine protease enzyme encoded by the PCSK9 gene and primarily synthesised in hepatocytes. Its central physiological role is to regulate the density of LDL receptors (LDLR) on the surface of liver cells — and through this mechanism, to control how much LDL cholesterol is cleared from the bloodstream.
The normal LDLR lifecycle works as follows: LDL particles in the blood bind to LDLR on the hepatocyte surface, are endocytosed into the cell, and the LDL is metabolised. The receptor then recycles to the cell surface to capture more LDL — each receptor can complete this cycle hundreds of times. PCSK9 disrupts this recycling: it binds to LDLR in the endosome and redirects it to the lysosome for degradation instead of allowing it to return to the surface. Fewer LDLR on liver cells → less LDL cleared from circulation → higher plasma LDL-C.
The clinical relevance of PCSK9 was discovered through human genetics. Individuals with gain-of-function PCSK9 mutations have reduced LDLR density, very high LDL-C, and early cardiovascular disease — resembling familial hypercholesterolaemia. Conversely, individuals with loss-of-function PCSK9 mutations have naturally low LDL-C and dramatically reduced lifetime cardiovascular event rates — with no apparent adverse health effects. This genetic validation made PCSK9 an ideal therapeutic target.
Key insight: Statins increase PCSK9 production by 20–30% as a compensatory response to reduced hepatic cholesterol synthesis. This partially limits the LDLR-upregulating effect of statins. PCSK9 inhibitors block this compensatory check — which is why the combination of statin + PCSK9 inhibitor is synergistic rather than merely additive.
How PCSK9 Inhibitors Work
All three approved PCSK9 inhibitors share the same ultimate mechanism: by reducing PCSK9 activity, they allow LDL receptors to recycle normally, increasing LDLR density on hepatocyte surfaces and dramatically increasing LDL-C clearance from the bloodstream. The difference is where in the PCSK9 pathway each drug acts.
Monoclonal Antibodies (Evolocumab & Alirocumab)
Evolocumab (Repatha) and alirocumab (Praluent) are fully human monoclonal antibodies that bind circulating PCSK9 protein in the bloodstream with high affinity, blocking it from binding LDL receptors. The PCSK9–antibody complex is cleared by the reticuloendothelial system. With PCSK9 neutralised, hepatocyte LDL receptors recycle normally, LDLR density increases 2–3 fold, and plasma LDL-C falls by 50–65% within 4 weeks of starting treatment. Both require subcutaneous injection every 2 weeks (or monthly for a higher dose of evolocumab).
siRNA (Inclisiran)
Inclisiran (Leqvio) works upstream — it delivers a small interfering RNA (siRNA) conjugated to GalNAc (N-acetylgalactosamine) that is selectively taken up by hepatocytes via the ASGPR receptor. Once inside the hepatocyte, the siRNA triggers RNA-induced silencing complex (RISC)-mediated degradation of PCSK9 mRNA, reducing PCSK9 protein synthesis at source. The result is the same — less PCSK9, more LDLR recycling, lower LDL-C — but the mechanism operates intracellularly rather than extracellularly. Because the siRNA is incorporated into RISC within cells, its duration of effect is much longer, enabling twice-yearly subcutaneous dosing after initial loading.
PCSK9 Inhibitors List
The following table summarises all three FDA-approved PCSK9 inhibitors as of 2026:
| Drug (Brand) | Company | Mechanism | FDA Approval | Dosing | LDL-C Reduction |
|---|---|---|---|---|---|
| Evolocumab (Repatha) | Amgen | Anti-PCSK9 mAb | August 2015 | 140 mg Q2W or 420 mg Q4W SC | ~60% |
| Alirocumab (Praluent) | Sanofi / Regeneron | Anti-PCSK9 mAb | July 2015 | 75–150 mg Q2W SC | ~50–60% |
| Inclisiran (Leqvio) | Novartis | siRNA (PCSK9 mRNA) | December 2021 | 284 mg SC: Day 1, Day 90, then Q6M | ~50% |
All three are administered by subcutaneous injection. Evolocumab and alirocumab are available as auto-injector pens for self-administration. Inclisiran is typically administered in a clinical setting given its infrequent dosing schedule.
PCSK9 vs Statins: When to Use Each
Statins and PCSK9 inhibitors address LDL-C through complementary mechanisms and are used at different points in the treatment algorithm.
PCSK9 Inhibitors vs Statins: Head-to-Head Comparison
| Feature | Statins | PCSK9 Inhibitors |
|---|---|---|
| Mechanism | Inhibit HMG-CoA reductase (↓ cholesterol synthesis → ↑ LDLR) | Block PCSK9 (allow LDLR recycling → ↑ LDLR) |
| LDL-C reduction | 30–55% | 50–65% (on top of statin) |
| Route | Oral, daily | Subcutaneous injection |
| Cost (monthly) | $5–30 (generic) | $400–1,200 (after rebates) |
| Myopathy risk | Yes (1–5% myalgia, rare rhabdomyolysis) | No |
| CV outcomes data | Multiple large RCTs (30+ years) | FOURIER (evolocumab), ODYSSEY (alirocumab) |
| First-line use | Yes | No — add-on or alternative when statin insufficient |
Clinical Trial Evidence
The FOURIER trial (27,564 patients with established ASCVD on statin therapy) demonstrated that evolocumab reduced LDL-C from a median of 92 mg/dL to 30 mg/dL and achieved a 15% relative risk reduction in the composite primary endpoint of major cardiovascular events (HR 0.85, 95% CI 0.79–0.92) over a median 2.2 years. (Source: Sabatine et al., NEJM 2017)
The ODYSSEY OUTCOMES trial (18,924 patients after acute coronary syndrome) showed alirocumab reduced LDL-C from 87 mg/dL to 40 mg/dL and reduced the primary endpoint of MACE by 15% relative risk (HR 0.85, 95% CI 0.78–0.93) over median 2.8 years. In patients with baseline LDL-C ≥100 mg/dL, absolute risk reduction was larger — 3.4 fewer events per 100 patients treated over 3 years. (Source: Schwartz et al., NEJM 2018)
Who Should Receive PCSK9 Inhibitors?
Current ACC/AHA and ESC/EAS guidelines recommend PCSK9 inhibitors in four scenarios:
- Heterozygous familial hypercholesterolaemia (HeFH) — LDL-C remains above goal despite maximally tolerated statin + ezetimibe
- Established ASCVD — prior MI, stroke, or PAD with LDL-C above 70 mg/dL (ESC very high risk) or 55 mg/dL (ESC extreme risk) on maximal statin
- Statin intolerance — unable to tolerate any statin dose; PCSK9 inhibitor as primary lipid-lowering agent
- Homozygous FH (HoFH) — evolocumab is approved in combination with LDL apheresis or other lipid-lowering therapy
PCSK9 as a Cardiovascular Biomarker
Beyond its therapeutic role as a drug target, circulating PCSK9 protein is itself measurable as a cardiovascular biomarker in research settings. Plasma PCSK9 concentrations correlate with LDL-C levels, vary with statin therapy (statins increase PCSK9 by 20–30%), and differ between individuals based on genetic variants — including the loss-of-function variants that confer cardiovascular protection.
PCSK9 measurement in plasma uses ELISA-based immunoassays employing anti-PCSK9 monoclonal antibodies. Research applications include: pharmacodynamic monitoring of PCSK9 inhibitor therapy, genetic variant characterisation studies, and investigation of PCSK9 as an independent cardiovascular risk predictor beyond LDL-C. The anti-PCSK9 antibodies used in therapeutic mAbs (evolocumab, alirocumab) are distinct from those used in research immunoassays — research assays require antibody pairs that detect both free and antibody-bound PCSK9 or specifically free PCSK9, depending on the pharmacodynamic question.
PCSK9 inhibitors are typically used alongside other cardiovascular risk markers. See our guides to cardiovascular inflammation markers (CRP, hs-CRP) and cardiac biomarkers (D-dimer) for a complete picture of cardiovascular risk assessment.
Anti-PCSK9 Antibody for Research & IVD
Sekbio develops anti-PCSK9 monoclonal antibodies for research immunoassay and IVD platform applications — including ELISA and lateral flow formats for circulating PCSK9 measurement in cardiovascular research studies.
Frequently Asked Questions About PCSK9 Inhibitors
What is PCSK9 and why does it matter for cholesterol?
PCSK9 is a liver enzyme that degrades LDL receptors (LDLR) on hepatocyte surfaces, preventing them from recycling. Fewer LDLR means less LDL cleared from the bloodstream — higher plasma LDL-C. Blocking PCSK9 allows receptors to recycle normally, increasing LDLR density 2–3 fold and reducing plasma LDL-C by 50–65%.
Human genetics established the importance of PCSK9: people with naturally occurring loss-of-function PCSK9 mutations have very low LDL-C and dramatically reduced cardiovascular disease risk throughout life, with no apparent adverse effects — validating PCSK9 as a safe and effective therapeutic target.
What PCSK9 inhibitors are currently available?
Three PCSK9 inhibitors are FDA-approved:
- Evolocumab (Repatha) — anti-PCSK9 mAb, Amgen, approved 2015; 140 mg Q2W or 420 mg Q4W SC
- Alirocumab (Praluent) — anti-PCSK9 mAb, Sanofi/Regeneron, approved 2015; 75–150 mg Q2W SC
- Inclisiran (Leqvio) — siRNA, Novartis, approved 2021; 284 mg SC twice yearly after loading
All three are delivered by subcutaneous injection. Evolocumab and alirocumab reduce LDL-C by ~50–60%; inclisiran by ~50%.
How much do PCSK9 inhibitors lower LDL cholesterol?
PCSK9 inhibitors reduce LDL-C by 50–65% on top of background statin therapy. In FOURIER, evolocumab reduced median LDL-C from 92 mg/dL to 30 mg/dL — a 59% reduction. In ODYSSEY, alirocumab reduced LDL-C from 87 mg/dL to 40 mg/dL.
As monotherapy in statin-intolerant patients, PCSK9 inhibitors reduce LDL-C by approximately 50–60% from baseline. Patients with familial hypercholesterolaemia and very high baseline LDL-C (200+ mg/dL) can typically achieve guideline-recommended targets of <55–70 mg/dL with statin + PCSK9 inhibitor combination.
Who should take PCSK9 inhibitors?
Guidelines recommend PCSK9 inhibitors for: (1) Heterozygous familial hypercholesterolaemia with LDL-C above goal on maximal statin + ezetimibe; (2) Established ASCVD (MI, stroke, PAD) with LDL-C above 70 mg/dL on maximal statin; (3) Statin intolerance — as primary lipid-lowering therapy; (4) Homozygous FH (evolocumab, with LDL apheresis).
PCSK9 inhibitors are not first-line — statins and ezetimibe should be optimised first before considering PCSK9 inhibition, except in statin-intolerant patients.
What are the side effects of PCSK9 inhibitors?
PCSK9 inhibitors have a favourable safety profile. The most common side effects are injection site reactions (3–5%) and nasopharyngitis. Unlike statins, they do not cause myalgia, myopathy, or rhabdomyolysis — making them the preferred option for statin-intolerant patients.
Long-term safety data from FOURIER (2.2 years) and ODYSSEY (2.8 years) show no significant excess serious adverse events versus placebo. Very low LDL-C levels achieved (<20 mg/dL) have not been associated with cognitive impairment or hormonal dysfunction in trial populations.
How do PCSK9 inhibitors compare to statins?
Statins and PCSK9 inhibitors are complementary. Statins reduce hepatic cholesterol synthesis → liver upregulates LDLR → lower LDL-C, but also upregulate PCSK9 (limiting the LDLR gain). PCSK9 inhibitors block this compensatory check, amplifying LDLR recycling and LDL-C lowering synergistically.
Statins are first-line: oral, daily, generic cost ~$5–30/month, 30–55% LDL-C reduction, decades of cardiovascular outcomes data. PCSK9 inhibitors are add-on: injectable, expensive (~$400–1,200/month after rebates), 50–65% additional LDL-C reduction on top of statin.
What is inclisiran and how is it different from evolocumab and alirocumab?
Inclisiran is an siRNA that silences PCSK9 mRNA inside hepatocytes, preventing PCSK9 protein synthesis at its source. Evolocumab and alirocumab are monoclonal antibodies that neutralise circulating PCSK9 protein after it is made.
The key practical difference is dosing: inclisiran requires only two injections per year (after Day 1 and Day 90 loading doses) — versus 24–26 injections per year for Q2W antibodies. LDL-C reduction is comparable (~50%). Inclisiran does not yet have cardiovascular outcomes trial data; its approval was based on LDL-C surrogate endpoint studies (ORION programme).